Physician profile
Rachel E Ferrell
NPI 1518397470
$374.16
in general payments reported to CMS, 2019-2025
11 companies · $33.30 in 2025
The $33.30 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.86 · 2022: $12.33 · 2023: $293 · 2024: $21.69 · 2025: $33.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $347.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $135.18 | 2023 | Liberty Select Cycler, Nxstage System One |
| Travere Therapeutics, INC. | $51.39 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.30 | 2025 | Entyvio |
| Mallinckrodt Hospital Products INC. | $32.09 | 2023 | Terlivaz |
| Vifor Pharma, INC. | $28.15 | 2023 | Veltassa |
| Baxter Healthcare | $21.69 | 2024 | Renal - Chronic |
| Otsuka America Pharmaceutical, INC. | $18.80 | 2023 | Jynarque |
| Glaxosmithkline, LLC. | $14.49 | 2023 | Benlysta |
| Janssen Pharmaceuticals, INC | $13.86 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.88 | 2023 | Farxiga |
| Aurinia Pharma U.S., INC. | $12.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Ferrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.